At Verona Pharma our vision is to become a leader in developing and commercializing innovative treatments to improve the health and quality of life of the millions of people affected by chronic respiratory diseases.
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.
Our proprietary lead candidate, ensifentrine (RPL554), is paving the way for a new generation of drugs, with a novel mode of action, and has the potential to provide relief for the many patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and possibly asthma.
Ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4), that act as both a bronchodilator and an anti-inflammatory agent in a single compound. There is no therapy currently available that acts as both a bronchodilator and anti-inflammatory in a single compound for the treatment of respiratory diseases. We believe ensifentrine has the potential to be the first novel type of bronchodilator in over forty years.
Verona Pharma is listed on the Nasdaq Global Market and the London Stock Exchange and is supported by a number of large, specialist healthcare focused investors from the US, UK and Europe.
On 29 November 2017 Verona Pharma won the Financing Deal of the Year at the 2017 Scrip Awards for its successful fundraising to support the continued growth of its clinical development programmes
We have established a management team and Board of Directors with extensive experience in large pharmaceutical and biotechnology companies in respiratory product development from drug discovery through commercialization and have played important roles in the development and commercialization of several approved respiratory treatments. They are supported by clinical and scientific advisors with industry and academic experience.
Our vision is to become a leader in developing innovative treatments for respiratory diseases with significant unmet medical needs. Our current focus is on our lead product candidate, ensifentrine (RPL554), which we believe has the potential to become an important and novel treatment for chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) and other respiratory diseases, including asthma.